Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Penumbra Inc. reported third-quarter 2025 revenue of $354.7 million, representing a 17.8% increase year-over-year on a reported basis and 16.9% growth on a constant currency basis.</li><li>The company's performance was supported by broad-based execution across its business segments and geographic regions.</li><li>U.S. revenue reached $275 million, up 21.5%, driven by core franchises such as thrombectomy and peripheral embolization.</li></ul>

Penumbra Inc. reported third-quarter 2025 revenue of $354.7 million, representing a 17.8% increase year-over-year on a reported basis and 16.9% growth on a constant currency basis.The company's performance was supported by broad-based execution across its business segments and geographic regions.U.S. revenue reached $275 million, up 21.5%, driven by core franchises such as thrombectomy and peripheral embolization.

Penumbra Goes All-In On Thrombectomy — Can STORM-PE Reshape Adoption?

<ul><li>Penumbra, a company engaged in the innovative medical devices sector, has recently reported its financial performance for the third quarter of 2025.</li><li>Total revenue for the quarter was $354.7 million, marking a year-over-year increase of 17.8% on a reported basis and 16.9% on a constant currency basis.</li><li>This growth evidences Penumbra's broad-based execution of its strategy and technological advancements, reflecting in significant progress across various business segments.</li></ul>

Penumbra, a company engaged in the innovative medical devices sector, has recently reported its financial performance for the third quarter of 2025.Total revenue for the quarter was $354.7 million, marking a year-over-year increase of 17.8% on a reported basis and 16.9% on a constant currency basis.This growth evidences Penumbra's broad-based execution of its strategy and technological advancements, reflecting in significant progress across various business segments.

Penumbra: STORM-PE Clinical Momentum & Physician Adoption—The Engine Behind Its Procedure Growth!

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.</li>
<li>In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.</li>
<li>Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.</li>
</ul>



Asahi Intecc (7747 JP) is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.
In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.
Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.


2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

<ul><li>Penumbra shares climbed approximately 3.8% on January 14, 2026, amid swirling takeover speculation that sparked renewed investor interest.</li><li>The move came as traders reacted to an "uncooked" alert issued by Betaville, a UK-based M&A rumor source, suggesting Penumbra may be the subject of acquisition interest.</li><li>Though no specific suitor was identified, the rumor mill was active, and speculative activity elevated trading volumes.</li></ul>

Penumbra shares climbed approximately 3.8% on January 14, 2026, amid swirling takeover speculation that sparked renewed investor interest.The move came as traders reacted to an "uncooked" alert issued by Betaville, a UK-based M&A rumor source, suggesting Penumbra may be the subject of acquisition interest.Though no specific suitor was identified, the rumor mill was active, and speculative activity elevated trading volumes.

Penumbra Heats Up as M&A Rumors Swirl– Is a $12B Buyout Coming?

<ul><li>Penumbra, Inc. reported its financial results for the third quarter of 2025, delivering solid performance across its business segments.</li><li>The company achieved a total revenue of $354.7 million, marking a year-over-year increase of 17.8% on a reported basis and 16.9% in constant currency.</li><li>This growth illustrates progress in executing Penumbra's strategy and enhancing its technological and market position.</li></ul>

Penumbra, Inc. reported its financial results for the third quarter of 2025, delivering solid performance across its business segments.The company achieved a total revenue of $354.7 million, marking a year-over-year increase of 17.8% on a reported basis and 16.9% in constant currency.This growth illustrates progress in executing Penumbra's strategy and enhancing its technological and market position.

Penumbra Ignites a Pulmonary Embolism Breakthrough—Hospitals Are Racing to Adopt It!

United States

Penumbra, Inc. designs, develops, manufactures, and markets medical devices. The Company offers peripheral vascular and neurovascular devices that help patients suffering from stroke and other neurovascular diseases. Penumbra operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Penumbra (PEN US)

Penumbra Goes All-In On Thrombectomy — Can STORM-PE Reshape Adoption?

Penumbra Inc. reported third-quarter 2025 revenue of $354.7 million, representing a 17.8% increase year-over-year on a reported basis and 16.9%...

Baptista Research

Penumbra: STORM-PE Clinical Momentum & Physician Adoption—The Engine Behind Its Procedure Growth!

Penumbra, a company engaged in the innovative medical devices sector, has recently reported its financial performance for the third quarter of...

Baptista Research

2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Asahi Intecc is poised for double-digit sales growth through FY26, driven by strong market demand for guidewires, market leadership positioning,...

Tina Banerjee

Penumbra Heats Up as M&A Rumors Swirl– Is a $12B Buyout Coming?

Penumbra shares climbed approximately 3.8% on January 14, 2026, amid swirling takeover speculation that sparked renewed investor interest. The...

Baptista Research

Penumbra Ignites a Pulmonary Embolism Breakthrough—Hospitals Are Racing to Adopt It!

Penumbra, Inc. reported its financial results for the third quarter of 2025, delivering solid performance across its business segments. The...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)